Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02832063 · ClinicalTrials.gov registry record · Phase 2
Clinical Trial in Subjects With Mild to Moderate Acne Vulgaris
A Phase 2 study of Acne Vulgaris, sponsored by AOBiome.
- Completed
- Registry status
- Phase 2
- Development phase
- 372
- Enrollment target
- 1
- Study location
NCT02832063: Completed Phase 2 study of Acne Vulgaris, sponsored by AOBiome.
NCT02832063 is a Phase 2 study of Acne Vulgaris that has completed, run by AOBiome. The registered enrollment target is 372 participants, above the 270-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (38% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02832063, a Phase 2 study of Acne Vulgaris, has completed, sponsored by AOBiome.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 372 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to demonstrate the safety, tolerability and efficacy of B244 administered over 12 weeks to participants with mild to moderate acne vulgaris relative to placebo.
Primary Outcome
Safety and tolerability endpoints will consist of all treatment related adverse events reporting during the study duration.
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL B244
Study Locations (1)
California
- Science37 - Culver City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 372 participants |
| Start Date | 2016-08 |
| Est. Completion | 2017-07-19 |
| Phase | Phase 2 |
What the finished NCT02832063 record still lists
NCT02832063 is an interventional study that assigns participants to a tested intervention. The registered 372 participants enrollment target is mid-sized for trials with a published cap, above the 270-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (38% higher).
The record links to 1 condition, with Acne Vulgaris appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02832063 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT02832063 about?
NCT02832063 is a clinical study titled "Clinical Trial in Subjects With Mild to Moderate Acne Vulgaris". The purpose of this study is to demonstrate the safety, tolerability and efficacy of B244 administered over 12 weeks to participants with mild to moderate acne vulgaris relative to placebo.
What is the current status of trial NCT02832063?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 372 participants. The study started on 2016-08. Estimated completion is 2017-07-19.
What conditions does trial NCT02832063 study?
This clinical trial studies the following conditions: Acne Vulgaris.
What interventions are being tested in trial NCT02832063?
The interventions under investigation include: Placebo (BIOLOGICAL), B244 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02832063?
This trial is sponsored by AOBiome, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02832063 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acne Vulgaris
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02832063's enrollment target sits among peer trials
372 20th of 67 higher than 48 of 67 other Acne Vulgaris trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acne Vulgaris trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris With Photodynamic Therapy in Adults
ACTIVE NOT RECRUITING · Phase 2
-
Dose Range Study of CD5789 in Acne Vulgaris
COMPLETED · Phase 2
-
An Evaluation of the Adrenal Suppression Potential and PK of CB-03-01 Cream in Pediatric Patients With Acne Vulgaris
COMPLETED · Phase 2
-
Photodynamic Therapy (PDT) With Methyl Aminolevulinate (MAL) Cream in Patients With Skin Type V or IV With Acne Vulgaris
COMPLETED · Phase 2
-
Efficacy and Safety Study of Gevokizumab to Treat Moderate to Severe Acne Vulgaris
COMPLETED · Phase 2
-
A Clinical Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04801589 · 372 participants · Phase 3
Goal-Directed Sedation in Mechanically Ventilated Infants and Children
- NCT04879329 · 372 participants · Phase 2
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
- NCT05318105 · 372 participants · NA
Ultrafiltration Versus IV Diuretics in Worsening Heart Failure
- NCT06797635 · 372 participants · Phase 2
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia